Devin T Corrigan, Ankit Tanwar, Meirong Du, Allison M Martin, Xingxing Zang
{"title":"B7-H3 （CD276）通路：新兴生物学和临床治疗","authors":"Devin T Corrigan, Ankit Tanwar, Meirong Du, Allison M Martin, Xingxing Zang","doi":"10.1016/j.tips.2025.08.008","DOIUrl":null,"url":null,"abstract":"<p><p>B7-H3 (CD276), an orphan member of the B7 family, is an immune checkpoint ligand and a tumor-associated antigen. Recent developments regarding dimerization, glycosylation, expression regulation, and effects on cell metabolism are emerging, along with a newfound role as a regulator of obesity. As a therapeutic target, ongoing clinical trials with antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) immune cells targeting B7-H3 have proved to be safe and effective across different human cancer types. Multiple new preclinical studies have also provided novel treatments targeting B7-H3, including TMIGD2 optimized potent/persistent (TOP) CAR cells, bispecific ADCs, CAR-natural killer (NK) cells, and T cell engagers. In this review we highlight the diverse emerging functions of B7-H3 in both physiological and pathological conditions, and discuss new therapies targeting this molecule.</p>","PeriodicalId":23250,"journal":{"name":"Trends in pharmacological sciences","volume":" ","pages":"975-988"},"PeriodicalIF":19.9000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12435905/pdf/","citationCount":"0","resultStr":"{\"title\":\"The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics.\",\"authors\":\"Devin T Corrigan, Ankit Tanwar, Meirong Du, Allison M Martin, Xingxing Zang\",\"doi\":\"10.1016/j.tips.2025.08.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>B7-H3 (CD276), an orphan member of the B7 family, is an immune checkpoint ligand and a tumor-associated antigen. Recent developments regarding dimerization, glycosylation, expression regulation, and effects on cell metabolism are emerging, along with a newfound role as a regulator of obesity. As a therapeutic target, ongoing clinical trials with antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) immune cells targeting B7-H3 have proved to be safe and effective across different human cancer types. Multiple new preclinical studies have also provided novel treatments targeting B7-H3, including TMIGD2 optimized potent/persistent (TOP) CAR cells, bispecific ADCs, CAR-natural killer (NK) cells, and T cell engagers. In this review we highlight the diverse emerging functions of B7-H3 in both physiological and pathological conditions, and discuss new therapies targeting this molecule.</p>\",\"PeriodicalId\":23250,\"journal\":{\"name\":\"Trends in pharmacological sciences\",\"volume\":\" \",\"pages\":\"975-988\"},\"PeriodicalIF\":19.9000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12435905/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in pharmacological sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.tips.2025.08.008\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.tips.2025.08.008","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics.
B7-H3 (CD276), an orphan member of the B7 family, is an immune checkpoint ligand and a tumor-associated antigen. Recent developments regarding dimerization, glycosylation, expression regulation, and effects on cell metabolism are emerging, along with a newfound role as a regulator of obesity. As a therapeutic target, ongoing clinical trials with antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) immune cells targeting B7-H3 have proved to be safe and effective across different human cancer types. Multiple new preclinical studies have also provided novel treatments targeting B7-H3, including TMIGD2 optimized potent/persistent (TOP) CAR cells, bispecific ADCs, CAR-natural killer (NK) cells, and T cell engagers. In this review we highlight the diverse emerging functions of B7-H3 in both physiological and pathological conditions, and discuss new therapies targeting this molecule.
期刊介绍：
Trends in Pharmacological Sciences (TIPS) is a monthly peer-reviewed reviews journal that focuses on a wide range of topics in pharmacology, pharmacy, pharmaceutics, and toxicology. Launched in 1979, TIPS publishes concise articles discussing the latest advancements in pharmacology and therapeutics research.
The journal encourages submissions that align with its core themes while also being open to articles on the biopharma regulatory landscape, science policy and regulation, and bioethics.
Each issue of TIPS provides a platform for experts to share their insights and perspectives on the most exciting developments in the field. Through rigorous peer review, the journal ensures the quality and reliability of published articles.
Authors are invited to contribute articles that contribute to the understanding of pharmacology and its applications in various domains. Whether it's exploring innovative drug therapies or discussing the ethical considerations of pharmaceutical research, TIPS provides a valuable resource for researchers, practitioners, and policymakers in the pharmacological sciences.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
